Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
- Figure 1 - alfuzosin fig1
- Figure 2 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 1 - alfuzosin fig2
- Figure 3 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 2 - alfuzosin fig3
- Figure 4 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 3 - alfuzosin fig4
- Figure 5 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 1 - alfuzosin fig5
- Figure 6 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2 - alfuzosin fig6
- Figure 7 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 3 - alfuzosin fig7
- Chemical Structure - alfuzosin str
- Label - lbl713352578
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 71335-2578 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - alfuzosin fig1
This text describes a study conducted on 8 healthy middle-aged male volunteers to compare the plasma concentration-time profiles of Alfuzosin after a single administration of Alfuzosin Hydrochloride Extended-Release Tablets 10 mg in both a fed and fasted state. The graph displays the mean Alfuzosin plasma concentration over time in ng/mL, showing differences in absorption between the two conditions.*
Figure 2 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 1 - alfuzosin fig2
This text provides information about the mean change from baseline in IPSS Total Symptom Score in Trial 1, involving the comparison between Placebo (H=167) and Alfuzosin Hydrochloride (H=170) on the days of treatment. The statistical significance is indicated by p <0.001.*
Figure 3 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 2 - alfuzosin fig3
Figure 4 — Mean Change from Baseline in IPSS Total Symptom Score: Trial 3 - alfuzosin fig4
This text provides information on the change from baseline in IPSS Total Symptom Score during Trial 3 related to a medical treatment. The data seems to be presented in a table or figure format for evaluation.*
Figure 5 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 1 - alfuzosin fig5
Figure 6 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2 - alfuzosin fig6
This text provides information about the mean change from baseline in peak urine flow rate over 5 days of treatment in Trial 2.*
Figure 7 — Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 3 - alfuzosin fig7
This text provides information about the mean change from baseline in peak urine flow rate during a clinical trial, specifically Trial 3. It appears to be related to a medical study or research project.*
Chemical Structure - alfuzosin str
Not available.*
Label - lbl713352578
Each extended-release tablet contains Alfuzosin Hydrochloride, USP 10 mg. This medication needs to be stored at 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). It must be kept away from children, protected from light and moisture, and dispensed in a tight, light-resistant container as defined in the USP. The tablets come in a pack of 30, repackaged by Bryant Ranch Prepack, Inc., and manufactured by Aurobindo Pharma Limited.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
